Sierra Oncology, Inc. (SRRA) News
Filter SRRA News Items
SRRA News Results
|Loading, please wait...|
SRRA News Highlights
- For SRRA, its 30 day story count is now at 18.
- Over the past 23 days, the trend for SRRA's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- The most mentioned tickers in articles about SRRA are RARE, DRUG and HA.
Latest SRRA News From Around the Web
Below are the latest news stories about Sierra Oncology Inc that investors may wish to consider to help them evaluate SRRA as an investment opportunity.
SAN MATEO, Calif., February 18, 2022--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, granted a stock option to one new employee as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan. The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such in
H Partners raised its investment in motorcycle giant Harley-Davidson. Warburg PIncus has a large stake in telemedecine firm SOC Telemed.
Sierra Oncology (NASDAQ:SRRA) said the underwriters of its previously announced public offering exercised in full their option to buy an additional 750K common shares at $27 per share. With this exercise, the gross proceeds to Sierra were ~$155.3M. Sierra intends to use the net proceeds to prepare for potential commercialization of...
SAN MATEO, Calif., February 03, 2022--Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced that the underwriters of its previously announced underwritten public offering exercised in full their option to purchase 750,000 additional shares of common stock at a price of $27.00 per share, before deducting underwriting discounts and commissions. With this exercise, the aggregate gross proceeds to Sie
SAN MATEO, Calif., February 03, 2022--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company will participate in the 4th Annual Guggenheim Oncology Conference being held virtually from February 9 – 11, 2022. President and Chief Executive Officer Stephen Dilly, MBBS, PhD, will participate in an analyst-moderated fireside chat on Thursday, February 10, 2022, at 12:00 pm ET.
Just when it looked like time to throw in the towel, the market pulled through and delivered a win. Ending January and going into February, the S&P 500 has racked up three consecutive days of gains, for a substantial rally that has investors giving a sigh of relief going forward. However, some Wall Street pros are still concerned that the volatility we have witnessed over the past weeks will increase in the months ahead. In this environment, investors are going to gravitate toward stocks that ha
SAN MATEO, Calif., January 31, 2022--Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the closing of its previously announced underwritten public offering of 4,074,075 shares of its common stock at a price to the public of $27.00 per share and, in lieu of shares of common stock, to a certain investor, pre-funded warrants to purchase up to 925,925 shares of common stock at a price to the publi
No summary available.
Sierra Oncology (NASDAQ:SRRA) has priced its upsized public offering of 4,074,075 common shares and, pre-funded warrants to purchase up to 925,925 shares of common stock. Shares are priced at $27.00/share and the pre-funded warrants are being offered at $26.999/warrant. Expected gross proceeds are ~$135M. Underwriters' over-allotment is an additional 750K...
LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Sierra Oncology (SRRA – Research Report) on January 25 and set a price target of $51.00. The company's shares closed last Wednesday at $28.64, close to its 52-week high of $29.48. According to TipRanks.com, Slutsky 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -4.8% and a 34.8% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences, Ventyx Biosciences, and BELLUS Health. Sierra Oncology has an analyst consensus of Strong Buy, with a price target consensus of $40.75, representing a 78.7% upside.